Class Action Legal News articles include legal news and lawsuit information about lawsuits filed, settlements reached and verdicts rendered in class action cases dealing with personal injury, defective products, bad drugs and other consumer law related news issues. Many of these articles include interviews from top legal professionals with guidance on legal recourse options from losses resulting from bad drugs, medical malpractice, investment fraud, personal injury, defective products and negligent employers.
Rockville, MD: A Food and Drug Administration (FDA) panel will meet in March to discuss the possibility of restricting sales of drugs including Procrit, Epogen and Aranesp. The drugs are all intended to fight anemia that is caused by chemotherapy; however, their safety has been called into question by recent studies.
Washington, DC: Concern about the incentives to overuse injectable cancer drugs, created by the Medicare reimbursement system that paid a markup of 20% to 100%, caused rates to be changed to more closely align with what doctors actually paid for the drugs, and reimbursement is now supposed to amount to only 6% more than the average price paid by all doctors.
Wastington, DC: The cancer industry derives most of its profits from chemotherapy. Both the drug companies and the treatment providers profit from the chemotherapy drugs and the medications used to combat the side effects. The obscene profits made off chemotherapy override any incentive to find a cure or better treatments.
Thousand Oaks, CA: A company that manufactures a trio of drugs to combat anemia is suffering anemic symptoms of its own, after two new studies have further clouded the safety and effectiveness of Amgen's anemia drugs.
Washington, DC: According to US Renal Data System and the Medicare Payment Advisory Commission, Medicare spends about $64,000 annually for each person on hemodialysis for all medical services, and the anemia drugs Procrit, Epogen and Aranesp are the single largest drug expense for Medicare.
Washington, DC: On July 20, 2007, the Centers for Medicare & Medicaid Services issued new reimbursement rules that limit the use and dosage for a class of anemia drugs known as erythropoiesis stimulating agents (ESA's), in large part prompted by findings that the medications were being over-prescribed for profit under the current billing rules.
Washington, DC: Due to their rampant off-label use, at a May 10, 2007, meeting, an FDA advisory panel voted 15-2 in favor of adding new restrictions on the use of the anemia drugs darbepoetin and epoetin, known as Erythropoiesis Stimulating Agents, the man-made versions of a hormone produced in the kidneys that prevents anemia.
Washington, DC: On May 9, 2007, the New York Times reported that drug makers Johnson & Johnson and Amgen are paying "hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines."
San Francisco, CA: A recent study has found that for-profit dialysis centers are over-using anti-anemia drug Epogen, putting patients at risk of suffering deadly side effects.
Washington, DC: To increase profits, drugs used to treat anemia in patients covered by Medicare are being given at higher doses and for conditions not approved by the FDA, due to reimbursement policies adopted by the Centers for Medicare and Medicaid Services under the leadership of top officials appointed by the Big Pharma-friendly Bush Administration.
Washington, DC: Medicare has provided coverage for all patients with End Stage Renal Disease since 1972, and according to the House Ways and Means Committee, the government pays for 93% of services provided to dialysis patients, at a cost of about $2 billion a year.
Please complete this form to request a review of your complaint by an attorney.
By submitting this form I agree to the Terms of Service.
There is absolutely no cost to you to submit this form. Doing so places you under no obligations and does not establish an attorney-client relationship.
